What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 3).

December 8, 2025BloodOpen Access

Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

JLJessica LiuBoston Children's Hospital AIAbel IncoomCommunity Health Alliance MSMaximilian StahlHarvard University

Discussion

Member takes

Implication

Prospective evaluation shows CTPM increases patient identification in myelodysplastic syndromes and myeloma trials, highlighting challenges in enrollment.

Key Points

CTPM improved patient identification but faced significant attrition leading to low enrollment.
Among the 216 identified patients for the MDS trial, only 11 were eligible, resulting in one enrollment.
Automated prescreening with electronic medical record data may enhance recruitment but highlights the need for better patient outreach.
Study findings underline the necessity of patient-centered trial designs to bolster enrollment in hematologic malignancies.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd47 https://doi.org/10.1182/blood-2025-1086

View Full Paper

Ask AI

Bookmark

Implication

Prospective evaluation shows CTPM increases patient identification in myelodysplastic syndromes and myeloma trials, highlighting challenges in enrollment.

Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider